Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has ...

BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the "Company"), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced ...

On Tuesday, CervoMed Inc (CRVO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-8.09 or -78.93% from the prior close of $10.25. The stock opened at $2.53 and touched a ...

Fintel reports that on December 10, 2024, D. Boral Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...

Canaccord lowered the firm’s price target on CervoMed (CRVO) to $12 from $65 and keeps a Buy rating on the shares. The firm said they announced ...

CervoMed (CRVO – Research Report) received a Sell rating and price target from Morgan Stanley analyst Jeffrey Hung today. The company’s ...

The latest in health news includes Zealand Pharma's obesity drug trial, a record dengue outbreak in the Americas, CervoMed's ...

CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, ...

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...